BC Extra | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being...
BC Innovations | Feb 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting IL-1α or IL-6 could help treat HER2-positive breast cancer. In patient tumor samples, levels of IL-1α or IL-6 were associated with poor metastasis-free survival, and...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Sep 22, 2017
Clinical News

CHMP reiterates negative opinion on XBiotech's Hutruo

EMA's CHMP reiterated its May negative opinion regarding an MAA from XBiotech Inc. (NASDAQ:XBIT) for Hutruo (Xilonix, CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat symptoms of advanced colorectal cancer, including cachexia, saying the data provided...
BC Extra | Sep 15, 2017
Company News

CHMP issues negative opinions

On Friday, EMA's CHMP issued negative opinions for a number of products, including Duchenne muscular dystrophy candidate Raxone idebenone (SNT-MC17) from Santhera Pharmaceuticals Holding AG (SIX:SANN). CHMP also said Bristol-Myers Squibb Co. (NYSE:BMY) withdrew an...
BioCentury | Jul 7, 2017
Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
BC Week In Review | Jun 16, 2017
Clinical News

XBiotech discontinues Xilonix CRC trial

XBiotech Inc. (NASDAQ:XBIT) said it is discontinuing the Phase III XCITE trial of Xilonix (CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat colorectal cancer in about 643 patients. An IDMC recommended the study's termination based on...
BioCentury | Jun 9, 2017
Finance

ASCO ascent

Investors were keenly focused on immunotherapy combinations containing PD-1/L1 and IDO inhibitors going into this year’s American Society of Clinical Oncology meeting, but the biggest gainers were companies that generated positive clinical data for other...
BC Extra | Jun 9, 2017
Clinical News

XBiotech sags after discontinuing Xilonix CRC study

XBiotech Inc. (NASDAQ:XBIT) plummeted $6.22 (66%) to $3.20 after it said it is discontinuing the Phase III XCITE trial of Xilonix to treat colorectal cancer (CRC). An IDMC recommended the study's termination based on an...
BC Week In Review | May 25, 2017
Clinical News

CHMP recommends against XBiotech's colorectal cancer candidate

EMA’s CHMP recommended against approval of an MAA from XBiotech Inc. (NASDAQ:XBIT) for Xilonix (Hutruo, CV-18C3, T2-18C3, RA-18C3, MABp1, CA-18C3) to treat symptoms of advanced colorectal cancer, including cachexia. CHMP cited lack of efficacy in...
Items per page:
1 - 10 of 48